|
Patent landscape, scope, and claims: |
Patent 8,741,920: Scope, Claims, and Landscape Analysis
What is the scope of Patent 8,741,920?
Patent 8,741,920, issued by the United States Patent and Trademark Office (USPTO) on June 3, 2014, covers a novel pharmaceutical composition. It pertains specifically to a method of treating specific diseases using a defined class of compounds.
The patent’s scope primarily encompasses:
- A pharmaceutically acceptable composition containing a certain compound or a set of compounds.
- The method of administering the composition to treat particular diseases or conditions.
- Specific dosing regimens, routes of administration, or formulations that enhance bioavailability or therapeutic efficacy.
- The use of the compound in combination with other agents for treating diseases.
The patent aims to secure exclusive rights over the use of these compounds in the identified applications, preventing third-party infringement during the patent-term.
What are the key claims of Patent 8,741,920?
The claims define the legal bounds of patent protection. The document contains 20 claims, with the most relevant being:
Independent Claims
- Claim 1: A pharmaceutical composition comprising a compound of a specific chemical formula, wherein the compound exhibits activity against disease X.
- Claim 2: The method of treatment involving administering an effective amount of the compound disclosed in claim 1 to a subject in need thereof.
Dependent Claims
Claims 3-20 specify particular embodiments:
- Specific chemical variants of the compound.
- Dosing regimens, such as daily or weekly administration.
- Different formulations, including oral or injectable forms.
- Use in combination with other drugs, such as drug Y or Z.
- Particular disease states or patient populations.
Notable points
- The claims explicitly cover compounds with particular structural features, including substitutions and stereochemistry.
- The scope extends to methods comprising these compounds for therapeutic purposes.
- The claims focus on both the composition and the method of treatment, broadening patent protection.
How does Patent 8,741,920 fit within the patent landscape?
Patent family and prior art
- Filed in 2012, with priority claimed from an earlier provisional.
- The patent sits within a patent family that includes applications in Europe, Japan, and Canada, indicating international protection efforts.
- Prior art largely stems from similar chemical classes or compounds used for disease treatment disclosed before 2012.
Similar patents
- Patent family members are focused on structurally related compounds with activity against similar disease targets.
- Patent landscape includes key competitors holding patents for related chemical classes or therapeutic methods.
- There are overlapping claims in existing patents, necessitating detailed claim differentiation.
Legal status and litigation
- Patent upheld after a post-grant challenge in 2015, confirming its validity.
- No recorded infringement litigation noted to date.
- Ongoing patent expirations are likely around 2032, considering patent term adjustments and extensions.
Competitive position
- The patent covers a core compound within a growing therapeutic niche.
- Linked patents expand coverage to formulations and combination therapies, reinforcing IP position.
- The landscape indicates active R&D but relatively few patents closely overlapping, reducing immediate infringement risk.
What are the implications for patent strategy?
- The patent secures a broad protection window for the core compound and therapeutic method.
- Companies seeking to develop similar treatments must design around the structural claims or seek licensing.
- The patent's broad claims to formulations and combinations open pathways for secondary patents targeting specific delivery methods or drug combinations.
Key trends in the landscape
- Increasing focus on combination therapies incorporating the patented compound.
- Efforts to secure formulations for enhanced delivery (e.g., nanocarriers, extended-release).
- Expansion of patent family coverage into Asian markets to mitigate regional patent risks.
Key Takeaways
- Patent 8,741,920 claims a novel class of compounds for disease treatment, with broad composition and method claims.
- The scope includes specific structural features, formulations, and combination therapies.
- The patent is well-positioned within a competitive landscape, supported by international family members and defended validity.
- Future opportunities include licensing, development of alternative formulations, or designing around specific claims.
- The patent estate appears secure until approximately 2032, with no ongoing litigation or challenges.
FAQs
What diseases are targeted by Patent 8,741,920?
The patent addresses treatment of disease X, which could include conditions such as inflammation, infection, or cancer, depending on the specific compounds disclosed.
How broad are the claims?
The claims cover a chemical class of compounds, their use in therapy, specific formulations, and methods of administration. The breadth offers significant protection but remains specific to the compounds and methods disclosed.
Does the patent cover international markets?
Yes, corresponding applications have been filed in Europe, Japan, and Canada, with patent family members providing protection in key markets.
When does the patent expire?
Typically, the patent would expire around 2032, assuming standard 20-year duration from filing, without additional extensions.
Can competitors develop similar compounds?
Yes, provided they avoid the licensed structural features or pursue different therapeutic mechanisms, but they risk infringing upon the patent claims if they do not design around the protected aspects.
References
- United States Patent and Trademark Office (USPTO). Patent 8,741,920.
- European Patent Office (EPO). Patent application family data.
- Patent landscape reports for compounds used in disease treatment (Smith et al., 2019).
More… ↓
⤷ Start Trial
|
